Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Alvarez, RD, Gray, HJ, Timmins, PF, Gibb, RK, Edelson, M, Fowler, JM, Havrilesky, LJ, McCauley, DL, Nash, JD, Rahaman, J, Rash, JK, Rodabaugh, KJ, Powell, MA, Bristow, RE, Brown, JV, Tewari, D, Cliby, WA, Anastasia, P, Robinson, WR, Shahin, MS, Cantrell, LA, Cloven, NG, Gold, MA, Hope, JM, Muntz, HG, Sorosky, JI, Elkas, JC, Frumovitz, MM, Jewell, E, Spillman, MA, and Naumann, RW. "We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies." Gynecol Oncol 129, no. 1 (April 2013): 3-4.

Scholars@Duke

Havrilesky, LJ, and Abernethy, AP. "Quality of life in ICON7: need for patients' perspectives." Lancet Oncol 14, no. 3 (March 2013): 183-185.

Full Text

Hess, LM, Brady, WE, Havrilesky, LJ, Cohn, DE, Monk, BJ, Wenzel, L, and Cella, D. "Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study." Gynecol Oncol 128, no. 2 (February 2013): 175-180.

Full Text

Secord, AA, Geller, MA, Broadwater, G, Holloway, R, Shuler, K, Dao, N-Y, Gehrig, PA, O'Malley, DM, Finkler, N, and Havrilesky, LJ. "A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer." Gynecologic Oncology 128, no. 1 (2013): 65-70.

Full Text

Secord, AA, Geller, MA, Broadwater, G, Holloway, R, Shuler, K, Dao, N-Y, Gehrig, PA, O'Malley, DM, Finkler, N, and Havrilesky, LJ. "A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer." Gynecologic Oncology 128, no. 1 (January 2013): 65-70.

Full Text

Wenham, RM, Lapolla, J, Lin, H-Y, Apte, SM, Lancaster, JM, Judson, PL, Gonzalez-Bosquet, J, Herschberger, A, Havrilesky, LJ, and Secord, AA. "A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy." Gynecologic Oncology 130, no. 1 (2013): 19-24.

Full Text

Phippen, NT, III, CAL, Miller, CR, Lowery, WJ, Havrilesky, LJ, and Barnett, JC. "Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer?." Gynecologic Oncology 130, no. 2 (2013): 317-322.

Full Text

Hess, LM, Brady, WE, Havrilesky, LJ, Cohn, DE, Monk, BJ, Wenzel, L, and Cella, D. "Comparison of methods to estimate health state utilities for ovarian cancer using quality of life data: A Gynecologic Oncology Group study." Gynecologic Oncology 128, no. 2 (2013): 175-180.

Full Text

Tergas, AI, Havrilesky, LJ, Fader, AN, Guntupalli, SR, Huh, WK, Massad, LS, and Rimel, BJ. "Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer." Gynecologic Oncology 130, no. 3 (2013): 421-425.

Full Text

Barnett, JC, Secord, AA, Cohn, DE, II, CAL, Myers, ER, and Havrilesky, LJ. "Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer." Cancer 119, no. 20 (2013): 3653-3661.

Full Text

Pages